Dry Eye Disease Pipeline, NDA Approvals, Clinical Trials 2023 (Updated) | Companies - Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and Others

DelveInsight's, "Dry Eye Disease Pipeline Insight 2023" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the Dry Eye Disease pipeline drug profiles, including Dry Eye Disease clinical trials and nonclinical stage products. It also covers the Dry Eye Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Dry Eye Disease Pipeline treatment landscape of the report, click here @ Dry Eye Disease Pipeline Outlook- https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dry Eye Disease Pipeline Insight Report
• DelveInsight's Dry Eye Disease pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline therapies.
• The leading Dry Eye Disease Companies include TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, Daewoong Pharmaceutical Co. LTD, Ocusoft Inc, and others.
• Promising Dry Eye Disease Pipeline Therapies include Reproxalap, Timbetasin, Visomitin, Varenicline Tartrate Nasal Spray, SI-614, sodium hyaluronate, CequaTM (Cyclosporine 0.09%) ophthalmic solution, 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®, Haporine-S, Restasis (cyclosporine 0.05%), SHR8028 eye drops, and others
• Reproxalap, a novel topically administered RASP inhibitor by Aldeyra Therapeutics, is currently in Phase III clinical development as a 0.25% ophthalmic solution for the treatment of dry eye disease and allergic conjunctivitis, two ocular inflammatory diseases that often occur together (NCT04735393).
• RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.
• Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

For further information, refer to the detailed Dry Eye Disease Unmet Needs, Dry Eye Disease Market Drivers, and Dry Eye Disease Market Barriers, click here for Dry Eye Disease Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Eye Disease Overview
Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance.

Request a sample and discover the recent advances in Dry Eye Disease Ongoing Clinical Trial Analysis and Medications, click here @ Dry Eye Disease Treatment Landscape- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Eye Disease Emerging Drugs Profile
• Reproxalap: Aldeyra Therapeutics
Reproxalap, is a novel small molecule drug candidate for Dry Eye. By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. In a Phase II b clinical trial, Aldeyra's lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

• Timbetasin: RegeneRx Biopharmaceuticals
RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.

• Visomitin: Mitotech
Visomitin, contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

Dive deep into rich insights for drugs for Dry Eye Disease Market Drivers and Dry Eye Disease Market Barriers, click here @ Dry Eye Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Eye Disease Pipeline Therapeutics Assessment
There are approx. 50+ Dry Eye Disease companies which are developing the Dry Eye Disease therapies. The Dry Eye Disease companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals.

Scope of the Dry Eye Disease Pipeline Report
• Coverage- Global
• Dry Eye Disease Companies- TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, Daewoong Pharmaceutical Co. LTD, Ocusoft Inc, and others.
• Dry Eye Disease Pipeline Therapies- Reproxalap, Timbetasin, Visomitin, Varenicline Tartrate Nasal Spray, SI-614, sodium hyaluronate, CequaTM (Cyclosporine 0.09%) ophthalmic solution, 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®, Haporine-S, Restasis (cyclosporine 0.05%), SHR8028 eye drops, and others.
• Dry Eye Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Dry Eye Disease Mergers and acquisitions, Dry Eye Disease Licensing Activities @ Dry Eye Disease Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Dry Eye Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Eye Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Timbetasin: RegeneRx Biopharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dry Eye Disease Key Companies
21. Dry Eye Disease Key Products
22. Dry Eye Disease - Unmet Needs
23. Dry Eye Disease - Market Drivers and Barriers
24. Dry Eye Disease - Future Perspectives and Conclusion
25. Dry Eye Disease Analyst Views
26. Dry Eye Disease Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.